Major international firms committed multiyear investments to strengthen South Korea’s biomedical sector. Roche pledged ₩710 billion (about US$485 million) over five years to expand clinical trial capacity and deepen R&D activities, while Eli Lilly committed US$500 million to bolster the country’s biopharma ecosystem following government engagement. Both agreements aim to position South Korea as a regional hub for clinical development, manufacturing, and innovation, including trial acceleration for common and hard‑to‑treat diseases. The investments include infrastructure, local partnerships, and commitments to run trials and develop products in the country. Policy context: these private‑sector commitments accompany national initiatives to attract inward investment and highlight South Korea’s growing role in global clinical development and commercialization strategies.